Featured News
858Wire StoriesExpo Bazaar USA — Digital B2B Marketplace for Retailers Seeking Artisanal Home Products From India — To Launch in March 2022
The first-of-its-kind online service connects independent specialty stores and designers with handicrafts, gifts and home décor merchandise from India DALLAS–(BUSINESS WIRE)–#artisanproducts–Expo Bazaar...
- 544Wire Stories
Japan Gift Card and Incentive Card Market Report 2022: Market is Expected to Grow by 10.7% to Reach $20,188.0 Million in 2022 – Forecast to 2026 – ResearchAndMarkets.com
DUBLIN–(BUSINESS WIRE)–The “Japan Gift Card and Incentive Card Market Intelligence and Future Growth Dynamics (Databook) – Q1 2022 Update” report has been...
- 528Wire Stories
Japan Gift Card and Incentive Card Market Report 2022: Market is Expected to Grow by 10.7% to Reach $20,188.0 Million in 2022 – Forecast to 2026 – ResearchAndMarkets.com
DUBLIN–(BUSINESS WIRE)–The “Japan Gift Card and Incentive Card Market Intelligence and Future Growth Dynamics (Databook) – Q1 2022 Update” report has been...
- 493Wire Stories
Japan Gift Card and Incentive Card Market Report 2022: Market is Expected to Grow by 10.7% to Reach $20,188.0 Million in 2022 – Forecast to 2026 – ResearchAndMarkets.com
DUBLIN–(BUSINESS WIRE)–The “Japan Gift Card and Incentive Card Market Intelligence and Future Growth Dynamics (Databook) – Q1 2022 Update” report has been...
- 560Wire Stories
ValenzaBio and Novelty Nobility Announce Exclusive License Agreement for Potential Best-in-Class Anti-c-KIT Monoclonal Antibody
BETHESDA, Md. & PANGYO, South Korea–(BUSINESS WIRE)–ValenzaBio, Inc., a biopharmaceutical company developing monoclonal antibody (mAb) therapeutics for autoimmune and inflammatory indications, and...
- 537Wire Stories
ValenzaBio and Novelty Nobility Announce Exclusive License Agreement for Potential Best-in-Class Anti-c-KIT Monoclonal Antibody
BETHESDA, Md. & PANGYO, South Korea–(BUSINESS WIRE)–ValenzaBio, Inc., a biopharmaceutical company developing monoclonal antibody (mAb) therapeutics for autoimmune and inflammatory indications, and...
- 512Wire Stories
ValenzaBio and Novelty Nobility Announce Exclusive License Agreement for Potential Best-in-Class Anti-c-KIT Monoclonal Antibody
BETHESDA, Md. & PANGYO, South Korea–(BUSINESS WIRE)–ValenzaBio, Inc., a biopharmaceutical company developing monoclonal antibody (mAb) therapeutics for autoimmune and inflammatory indications, and...
- 736Wire Stories
JCR Pharmaceuticals’ Research Presentations at WORLDSymposium™ 2022 Showcase JR-141 (Pabinafusp Alfa) and Other Investigational Treatments for Lysosomal Storage Disorders
– Presentations Highlight Potential Benefits of Therapies Incorporating J-Brain Cargo®, JCR’s Proprietary, Blood-Brain Barrier-Penetrating Technology – HYOGO, Japan–(BUSINESS WIRE)–JCR Pharmaceuticals Co., Ltd....
- 688Wire Stories
JCR Pharmaceuticals’ Research Presentations at WORLDSymposium™ 2022 Showcase JR-141 (Pabinafusp Alfa) and Other Investigational Treatments for Lysosomal Storage Disorders
– Presentations Highlight Potential Benefits of Therapies Incorporating J-Brain Cargo®, JCR’s Proprietary, Blood-Brain Barrier-Penetrating Technology – HYOGO, Japan–(BUSINESS WIRE)–JCR Pharmaceuticals Co., Ltd....
- 718Wire Stories
JCR Pharmaceuticals’ Research Presentations at WORLDSymposium™ 2022 Showcase JR-141 (Pabinafusp Alfa) and Other Investigational Treatments for Lysosomal Storage Disorders
– Presentations Highlight Potential Benefits of Therapies Incorporating J-Brain Cargo®, JCR’s Proprietary, Blood-Brain Barrier-Penetrating Technology – HYOGO, Japan–(BUSINESS WIRE)–JCR Pharmaceuticals Co., Ltd....
- 539Wire Stories
Asia Pacific Buy Now Pay Later Markets and Investment Opportunities Report 2022: BNPL Payments are Expected to Grow by 61.5% to Reach US$133,696.8 Million in 2022 – Forecast to 2028 – ResearchAndMarkets.com
DUBLIN–(BUSINESS WIRE)–The “Asia Pacific Buy Now Pay Later Business and Investment Opportunities – 75+ KPIs on Buy Now Pay Later Trends by...
